Description of a Current Outbreak of <i>Mycoplasma pneumoniae</i> in the United States
During the COVID-19 pandemic, a significant decline in <i>Mycoplasma pneumoniae</i> was observed; however, <i>M. pneumoniae</i> re-emerged globally in 2023. Here, we describe a current outbreak of <i>M. pneumoniae</i> infections in the United States (US). More tha...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/14/1/60 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | During the COVID-19 pandemic, a significant decline in <i>Mycoplasma pneumoniae</i> was observed; however, <i>M. pneumoniae</i> re-emerged globally in 2023. Here, we describe a current outbreak of <i>M. pneumoniae</i> infections in the United States (US). More than 287 million patient records from all 50 states in the US were reviewed to identify patients with a <i>M. pneumoniae</i> diagnosis between 1 January 2017 and 30 September 2024. A c-chart was created by calculating the mean and standard error (SE) of cases during the pre-COVID-19 pandemic period, with the upper control limit (UCL) set at 3 SE above the mean. The presence of an outbreak was defined as counts above the UCL. Cumulative excess cases were used to estimate the magnitude of the outbreak, and the fold increase was calculated. A US outbreak of <i>M. pneumoniae</i> began at the end of 2023, resulting in 9708 excess cases corresponding to a 9.0-fold increase over the baseline UCL. The outbreak is ongoing, affects both children and adults, and includes patients with <i>M. pneumoniae</i> community-acquired pneumonia requiring hospitalization. This US outbreak of <i>M. pneumoniae</i> has significant implications for the management of patients with respiratory infections during the current pneumonia season. |
|---|---|
| ISSN: | 2076-0817 |